This trial will test whether istradefylline can improve cognition in people with Parkinson's disease who also have cognitive impairment.
- Parkinson's Disease
- Cognitive Impairment
1 Primary · 15 Secondary · Reporting Duration: Baseline to 26 weeks
Side Effects for
1 Treatment Group
Usual care plus istradefylline
1 of 1
10 Total Participants · 1 Treatment Group
Primary Treatment: Istradefylline · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 6 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
How many individuals have been enlisted for this experiment?
"That is correct. Clinicaltrials.gov suggests that this medical experiment, which was first listed on July 18th 2022, is presently enrolling patients and required 10 participants from 1 particular location." - Anonymous Online Contributor
What potential risks does Istradefylline pose to those who take it?
"Istradefylline's safety rating is 2, as there is some evidence to suggest its safety but no information yet on how effective it may be." - Anonymous Online Contributor
Are there current opportunities for participants to join this medical experiment?
"Affirmative. The clinicaltrials.gov webpage reveals that this investigation is actively recruiting participants, having first been posted on 18 July 2022 and last updated on 10 August 2022. In total, they are looking to enrol 10 people at a single trial site." - Anonymous Online Contributor